Steven Kelly, President and CEO  Oct. 12 | 10:45am | Oxford Biomedica Ballroom  Philadelphia, PA  (Private)  In-person Presentation  Carisma Therapeutics’ innovative approach has the potential to create life-changing cellular therapies for patients with cancer and other serious disorders.  www.carismatx.com  ...

Xavier Avat, Chief Business Officer  Oct. 12 | 12:00pm | Oxford Biomedica Ballroom  San Diego, CA  (NASDAQ: CAPR)  In-person Presentation  Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Our innovative technology builds upon...

Steven Nichtberger, M.D., President and CEO  Oct. 11 | 10:45am | Oxford Biomedica Ballroom  Philadelphia, PA  (NASDAQ: CABA)  In-person Presentation  Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment...

Haro Hartounian, Ph.D., CEO  Oct. 11 | 9:30am | Oxford Biomedica Ballroom  Newark, NJ  (Private)  In-person Presentation  BioCentriq is a premier cell and gene therapy development and manufacturing center located in New Jersey. The company operates multiple GMP and process development facilities and has in-house analytical method development capabilities....

Rick Fair, President and CEO  Oct. 11 | 4:30pm | Oxford Biomedica Ballroom  Houston, TX  (NASDAQ: BLCM)  In-person Presentation  Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective...

Christopher Vann, Chief Operating Officer  Oct. 12 | 4:45pm | UBC Ballroom  London, UK  (NASDAQ: AUTL)  In-person Presentation  Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is...

Pascal Touchon, President and CEO  Oct. 12 | 4:30pm | UBC Ballroom  San Franciso, CA  (NASDAQ: ATRA)  In-person Presentation  Atara Biotherapeutics is a pioneer in T cell immunotherapy, leveraging its novel allogeneic EBV T cell platform to develop transformative therapies for patients with serious diseases. With our lead program in Phase III clinical development...

Xiaokui Zhang, Ph.D., Chief Scientific Officer  Oct. 11 | 9:15am | Oxford Biomedica Ballroom  San Diego, CA  (Private)  In-person Presentation  Aspen Neuroscience is a development-stage, private biotechnology company focused on personalized cell therapies. We are developing autologous (the patient’s own) induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need,...

Diana Brainard, M.D, CEO  Oct. 12 | 2:30pm | UBC Ballroom  Waltham, MA  (NASDAQ: ALVR)  In-person Presentation  AlloVir is a late clinical-stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in immunocompromised patients. The company’s innovative, proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells (VSTs)...

Shelley Hartman, CEO Oct. 11 | 11:45am | Oxford Biomedica Ballroom   Woburn, MA  (Private)  In-person Presentation  Aegle Therapeutics is a pioneer in the development of extracellular vesicle (EV) therapy. We are focused on rare diseases, including epidermolysis bullosa (EB), and burns. Aegle has a proprietary EV harvesting technology that is critical...

By using this website you agree to accept our Privacy Policy and Terms & Conditions